MedTrace Logo

Effects of Exendin(9-39) on Gastroduodenal Motility

NCT00468091 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2015-04-01

No results posted yet for this study

Summary

The purpose of this study in humans is to define the effects of the endogenous hormone GLP-1 on gastroduodenal motility and on endocrine pancreatic secretion by using the specific GLP-1 receptor antagonist exendin(9-39). To elucidate possible cholinergic pathways, we combined exendin(9-39) with the muscarinergic antagonist atropine.

Conditions

  • Digestive Physiology
  • Gastrointestinal Motility
  • Gastrointestinal Hormones
  • Glucagon-like Peptide 1
  • Exendin (9-39)

Interventions

DRUG

exendin(9-39)amide

DRUG

atropine

Sponsors & Collaborators

  • German Research Foundation

    collaborator OTHER

  • Philipps University Marburg

    collaborator OTHER

  • Ludwig-Maximilians - University of Munich

    lead OTHER

Principal Investigators

  • Joerg Schirra, MD · Clinical Research Unit, Dept. of Internal Medicine II, University of Munich

Study Design

Allocation
RANDOMIZED
Purpose
DIAGNOSTIC
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
1999-02-28
Completion
2000-09-30

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00468091 on ClinicalTrials.gov